☸️ SAIMSARA — Public Sessions

EMA approval is not the end of evidence generation, but the start of a lifecycle in which uncertainty must be resolved through post-authorization studies, pharmacovigilance, RWE, and reimbursement reassessment. This evidence map shows where regulatory access, conditional authorization, surrogate endpoints, safety monitoring, and real-world confirmation succeed — and where they still leave clinicians, payers, and patients with critical unanswered questions.

FDA approval is not always the end of uncertainty — this evidence map shows how surrogate endpoints, accelerated pathways, thin pivotal trials, underrepresented populations, and delayed confirmatory evidence can leave major clinical questions unresolved after approval. The full evidence map helps clinicians, researchers, and policy-minded readers distinguish regulatory authorization from proven real-world benefit, safety, equity, and patient-centered value.

Surgical loupes are not just magnifying glasses — they are practical visualization tools for microsurgery, aesthetic precision, reconstruction, dental procedures, and surgeon ergonomics. This evidence map shows where loupes can match microscopes, where they improve workflow, and where advanced visualization remains necessary.

This review maps 29 original studies comparing barefoot, minimalist, mobility, and conventional footwear across gait biomechanics, foot morphology, stability, knee loading, and performance. It shows where barefoot-like footwear may be useful — fall-risk stability, intrinsic foot strength, and knee OA load reduction — and where conventional shoes still matter, especially for impact moderation and postoperative walking capacity.

Neuroleptic side effects are not only an EPS problem: the evidence map shows how motor toxicity, metabolic burden, endocrine disruption, sedation, autonomic effects, and patient-reported distress shift across drug classes and vulnerable populations. The full evidence map helps clinicians and researchers see where antipsychotics reduce risk, where they simply move toxicity into another domain, and why structured side-effect monitoring is essential in real-world care.

AI can already imitate parts of executive work — drafting CEO-style messages, supporting decisions, and simulating crisis responses — but the evidence shows that authority, trust, ethics, and accountability still remain deeply human problems. The full SAIMSARA evidence map reveals where AI may genuinely augment leadership, where it becomes symbolic hype, and why the future CEO is more likely to be human-with-AI than AI-alone.

Spinal cord stimulation is not simply an implant for chronic pain — it is a long-term neuromodulation pathway where benefit depends on careful selection, anatomy-aware implantation, psychosocial screening, and active device management. The full paper maps 270 references across 631 original studies to show where SCS is strongest, where complications cluster, and which patients may gain durable value rather than repeated revision or explantation.

Vascular closure devices are not simply tools to close a puncture site — they are workflow-enabling technologies whose value depends on anatomy, sheath size, imaging guidance, device selection, and bailout readiness. The full evidence map shows where VCDs accelerate hemostasis, ambulation, and discharge, and where complications cluster across femoral, large-bore, venous, TAVR, EVAR, ECMO, PCI, and electrophysiology settings.

Impella is not a simple “more support means better outcome” device: across 194 references and 432 original studies, the evidence shows a constant trade-off between ventricular unloading, survival signals, and complications such as bleeding, hemolysis, thrombocytopenia, vascular injury, and acquired von Willebrand syndrome. The full ☸️SAIMSARA evidence map shows where Impella appears strongest — early AMI-cardiogenic shock support, high-risk PCI, bridge-to-transplant/LVAD pathways, and selected RV failure scenarios — and where the evidence remains fragile, observational, or safety-limited.

Alcohol and depression are not a simple “alcohol causes depression” story: across 185 references and 3,711 original studies, the evidence separates moderate-use signals from the consistent harms of heavy drinking, AUD, coping-motivated use, suicidality, relapse, and mortality. The full ☸️SAIMSARA evidence map gives a reference-linked view of where causality remains uncertain, which mechanisms matter clinically, and why integrated screening and treatment are needed instead of treating alcohol and depression as separate problems.

Electronic health records are not won by one “best” vendor: the evidence shows that usability, clinical decision support, interoperability, analytics readiness, workflow fit, and governance decide whether an EHR actually improves care. Built from 57 references and 130 original studies, the full ☸️SAIMSARA evidence map gives a practical, reference-linked view of what makes EHR systems work — and where they fail in real clinical settings.

Behçet’s disease is far more than recurrent mouth ulcers: this evidence map shows it as a whole-body inflammatory vasculitis that can threaten vision, veins, arteries, brain, gut, and quality of life. The full review explains which diagnostic signals, genetic mimics, and modern therapies — especially anti-TNF agents, apremilast, colchicine, and emerging JAK inhibitors — may change how Behçet’s disease is recognized and treated.